Top Precision Medicine Stocks 2026: The One-Size-Fits-One Era

Here's how medicine worked for about 2,000 years:

Doctor looks at you. Doctor guesses. Doctor prescribes. If it doesn't work... guess again.

Precision medicine is the end of guessing. You sequence the tumor, the blood, the genome. You find out exactly what's broken. Then you pick the drug (or the trial, or the surgery) that matches.

Simple idea. Took 20 years and a few hundred billion dollars to get here. But 2026 is the year it started becoming a big business.^[1]

Look at the second quarter that just wrapped:

• Guardant's revenue grew 44%.
• Caris's revenue grew 45%.
• Natera's revenue grew 38%, and it ran more than a million tests in one quarter.
• Tempus posted its first-ever GAAP profit.
• Abbott paid $21 billion in cash for Exact Sciences.
• Freenome went public.
• Intellia got the first-ever Phase 3 win for an in-body CRISPR drug.

That's a sector finally waking up.

In precision medicine, the money is in the tests that tell you which drug to use, not the drugs. Not yet. Medicare and the big insurers finally started paying real prices for those tests. Signatera at ~$1,275 per test. Shield at ~$800. Tempus about to get another $200 per test starting in 2027. Volume times price.

Medicine used to be one-size-fits-all. Now it's one-size-fits-you. And somebody has to sell the tape measure.

We're slicing this sector by where in the patient's journey the company makes money:

1. Detection — find the cancer before symptoms. Blood test, not colonoscopy.
2. Profiling & Monitoring — you have cancer. What kind, exactly? Is it coming back?
3. Giants & Toolmakers — the sequencers, the platforms, and the conglomerates that own a piece of everything.
4. Therapeutics — drugs built for a specific gene, not a general population.

This is the sexy part. A tube of blood, drawn at your annual physical, that says "hey, there's something in your colon" or "there's a cancer signal, and it's probably pancreatic." Catch it at Stage 1 instead of Stage 4 and survival rates flip from terrible to excellent.

The science is solved. The hard part now is getting insurers, guidelines, and primary care doctors to actually order the thing. That's what changed in 2026.

Guardant Health NASDAQ: GH

Guardant Health was a liquid-biopsy company for late-stage cancer patients. Then it built Shield, a blood test for colorectal cancer screening, and became something much bigger.

Q2 2026 was the quarter Shield went mainstream. About 66,000 tests, up from 16,000 a year ago. The American Cancer Society put Shield in its screening guidelines. UnitedHealth became the first major commercial insurer to cover it. Guardant raised its full-year Shield volume guidance to 270,000–285,000 tests. Meanwhile the legacy oncology business grew 63% in volume, because the Guardant360 tests keep getting new FDA companion-diagnostic approvals.

The catch: Guardant is spending like a company that sees an open field. Sales and marketing went from $108M to $172M in one year. Free cash flow burn for 2026 is expected around $200M. Shield costs about $410 to run and sells for about $800, so the margin exists, but they're reinvesting every dollar of it. You're betting that the land grab works.

GRAIL NASDAQ: GRAL

GRAIL makes Galleri, the test that looks for 50+ cancers at once from a single blood draw. It's been on the market since 2021 as a lab-developed test, but without FDA approval, without Medicare coverage, and without insurance. People pay cash.

That could change fast. GRAIL filed for FDA premarket approval on the back of two enormous studies: a 25,000-person U.S. trial and the 140,000-person NHS-Galleri trial in England, the only randomized controlled trial any multi-cancer test has ever run. The FDA advisory panel meets September 23, 2026. If it goes well, Galleri becomes the first FDA-approved multi-cancer blood test, and Medicare coverage becomes a real conversation.

Q2 numbers: 61,000+ tests, revenue up 26% to $44.7M, net loss $110M. Samsung just put in $110M. Cash runway reportedly into 2030. This one is a binary event stock right now.

Freenome NASDAQ: FRNM

Freenome is the newest name on this list. It closed its SPAC merger with Perceptive Capital on July 20, 2026, and started trading on Nasdaq the next day with roughly $310M in fresh cash from a PIPE led by Perceptive Advisors and RA Capital.

Why care? Freenome's approach is "multiomics": it doesn't just read DNA in the blood, it reads proteins and methylation patterns too, then lets machine learning sort the signal from the noise. It has partnerships with both Roche and Exact Sciences (now Abbott), and management has talked about a 2026 commercial launch for colorectal and lung screening tests.

SPAC-born companies are volatile, and Freenome is competing directly with Guardant's Shield in the same colon-screening market. Treat it as the high-beta way to play Detection. Watch the first few quarters of reported numbers closely, because right now there's very little public track record to judge.

Detection finds the cancer. Profiling names it. Not "lung cancer" but "EGFR-mutant, PD-L1-high, MSI-stable lung cancer," which tells the oncologist which of 30 drugs has a shot.

Then Monitoring: after surgery, is it truly gone? A tumor-informed blood test can see recurrence months before a CT scan can. That's minimal residual disease (MRD) testing, and it's the fastest-growing product category in the whole sector.

Tempus AI NASDAQ: TEM

Tempus is the company that sells genomic tests and sells the resulting data back to pharma. Two businesses feeding each other. Diagnostics revenue grew 20% in Q2; the Data & Applications business grew 28% and just delivered the first version of a foundation model to AstraZeneca.

Tempus reported its first GAAP profit in Q2, $5.6M. Tiny, but symbolic. Full-year 2026 guidance went up to ~$1.6B in revenue. The FDA also approved its tumor-only xT CDx test, which unlocks a higher Medicare price starting in 2027, worth an estimated $85M a year in pure margin.

Tempus is also buying Personalis (~$1.5B enterprise value) to bulk up its MRD business, which grew test volume 38% in one quarter. The deal is expected to close late Q4 2026 or early 2027. The knock on Tempus has always been valuation. The response is: it's growing 25% and it's now profitable.

Caris Life Sciences NASDAQ: CAI

Caris does the deepest profiling of anyone. Where competitors sequence a few hundred genes, Caris runs whole-exome and whole-transcriptome sequencing on every patient. More expensive up front, but the resulting database (1.13 million profiles and counting) is something pharma will pay for.

Caris IPO'd in June 2025 and has been a machine since. Q2 2026: revenue +45% to $263.7M, gross margin 68% (up 500 basis points in a year), adjusted EBITDA +$55.7M, positive free cash flow. It raised full-year guidance to $1.03–$1.04B.

Case volume grew "only" 18%, so most of the revenue growth came from better pricing and collections. That's a great sign for margins, but it means you should watch whether volume growth reaccelerates. The MI Cancer Seek companion-diagnostic footprint expanding into more indications is the thing to track.

Natera NASDAQ: NTRA

Natera started in prenatal genetics and became the MRD king almost by accident. Signatera, its tumor-informed recurrence test, ran about 283,000 clinical units in Q2, up 56% year over year and up 34,000 sequentially, the biggest quarterly jump the company has ever recorded.

Two milestones this year that really matter: in May, the FDA approved Signatera as a companion diagnostic in bladder cancer, the first MRD test ever to get that label. And the average selling price hit ~$1,275, with management still targeting ~$2,000 long-term as more Medicare coverage decisions come through.

Q2 revenue was $753M, up 38%. Full-year guidance went up $100M to $2.85–$2.91B. The company says it'll be cash-flow positive for 2026 even while spending heavily on early cancer detection research. Natera is the "everything's working" name on this list, and it's priced like it.

Every test above runs on a sequencer. And every time a small company proves a market exists, a big one shows up with a checkbook. This segment is how you own the sector without betting on a single blood test.

Illumina NASDAQ: ILMN

Illumina makes the sequencers. Something like 80%+ of the world's DNA reads go through its machines. The research market has been soft for two years (grant funding cuts, China restrictions), but the clinical market, meaning all the companies above, is on fire.

Q2 2026: revenue up 9.5% to $1.16B, clinical consumables up 15% outside China, U.S. clinical up 20%+. NovaSeq X placements above 95 units for the third straight quarter. Guidance raised twice this year. EPS guidance now $5.30–$5.40.

The worry has a name: Axelios. Roche just launched a competing sequencer that promises a $150 genome. Illumina's answer is that clinical customers don't switch platforms lightly, and 83% of its sequencing volume has already migrated to NovaSeq X. Watch consumables growth. If clinical labs keep buying reagents at mid-teens growth, the moat holds.

Roche OTCQX: RHHBY

Roche is the only company on this list with a foot in every segment. It owns Foundation Medicine (tumor profiling). It agreed in May to buy PathAI (AI pathology). Its pharma arm makes the targeted drugs those tests point to. And on June 29 it launched Axelios 1, a completely new kind of sequencer that reads DNA by stretching it into "Xpandomers" 50x longer than the original molecule and pushing them through nanopores.

Axelios is research-use-only for now, list price $750,000, same-day whole-genome sequencing. Roche has said plainly that the clinic is the goal. If it gets there, Roche owns the pipe, the test, and the drug.

Roche is a $200B+ Swiss pharma. Precision medicine is a slice, not the whole pie. But it's the slice growing fastest, and this is the lowest-risk name here.

Abbott NYSE: ABT

Abbott closed its $21B all-cash purchase of Exact Sciences on March 23, 2026. That brought in Cologuard (the stool-based colon cancer test doing roughly $3B a year), Oncotype DX (breast cancer treatment guidance), Oncodetect (MRD), and Cancerguard (a multi-cancer blood test).

Abbott has one of the biggest primary-care sales forces in the world. Cologuard was already the default non-colonoscopy screen. Now Abbott gets to bundle it, and eventually Cancerguard, into every doctor's office it already visits. That's the direct competitive threat to Guardant's Shield and GRAIL's Galleri.

Precision medicine will be maybe 5–7% of Abbott's revenue. If you want exposure with a dividend and a balance sheet, this is it. If you want torque, look elsewhere.

The tests are useless without drugs that act on what they find. Most of the targeted-drug money sits inside big pharma. But a handful of smaller companies are building drugs that only make sense because we can now read the patient's genome. Two stand out in 2026.

Intellia Therapeutics NASDAQ: NTLA

Intellia is about to do something nobody has done: get a CRISPR drug approved that edits genes inside the body. (The existing approved CRISPR therapy edits cells outside the body and re-infuses them.)

The drug is lonvo-z for hereditary angioedema, a rare disease that causes unpredictable, sometimes fatal swelling attacks. In the Phase 3 HAELO trial, a single infusion cut attacks by roughly 90%, and most patients were freed from both attacks and chronic medication. The results were published in the New England Journal of Medicine in June. Intellia started a rolling FDA submission in April, expects to complete it in the second half of 2026, and plans to launch in the first half of 2027 if approved.

This is the cleanest "precision" story on the list: one gene, one edit, one dose. The risk is commercial. HAE already has good chronic treatments, so Intellia has to convince patients that a permanent edit beats a monthly injection. Also watch nex-z, the second program in ATTR amyloidosis, which came off a clinical hold this year and is enrolling Phase 3 again.

Praxis Precision Medicines NASDAQ: PRAX

Praxis builds drugs for epilepsies caused by specific gene mutations. Relutrigine targets kids with SCN2A and SCN8A mutations, conditions with no approved therapy today. It has priority review at the FDA with a decision date that was set for late September 2026 (check for extensions before trading around it). Ulixacaltamide for essential tremor has a PDUFA date of January 29, 2027.

Behind those, vormatrigine for common focal epilepsy and elsunersen (an antisense drug for SCN2A) both have pivotal readouts in 2026. Management claims $20B+ in combined peak revenue potential across the four assets. Take $20B claims from a company with zero revenue with a very large grain of salt.

Praxis has about $1.4B in cash, runway into 2028, and a stock that has already run hard on the Phase 3 wins. This is a "buy the approval, sell the launch stumble" kind of name. Size it accordingly.

Failure mode #1: Nobody pays. Every company in the Detection and Profiling segments lives or dies on reimbursement. A test that costs $400 to run and reimburses at $0 is a charity. Medicare's MolDX program decides which cancer types Signatera gets paid for; ADLT status decides what Tempus and Guardant get paid per test; commercial insurers follow guidelines that update slowly. Watch every coverage decision like an earnings report.

Failure mode #2: The test cries wolf. Multi-cancer detection lives on a knife edge. Too many false positives means healthy people get scans, biopsies, and anxiety for nothing, and the FDA and payers walk away. The Galleri advisory panel on September 23 is the first time a regulator will weigh in publicly on that trade-off. A rough panel sets the whole multi-cancer category back years, not just GRAIL.

The sleeper risk: commoditization. Roche is promising a $150 genome. If sequencing becomes as cheap as a blood-count panel, the toolmakers' margins shrink and the value moves entirely to whoever owns the patient data and the doctor relationship. That's good for Tempus, Caris, and Natera. Less good for Illumina.

The next 12–18 months are unusually dense with hard catalysts. In rough date order:

• September 23, 2026 — FDA advisory panel on GRAIL's Galleri. The single biggest event in the sector this year.
• Late September 2026 — FDA decision on Praxis's relutrigine (priority review; confirm the date).
• H2 2026 — Intellia completes the lonvo-z BLA; FDA acceptance and review timeline follow. Praxis vormatrigine and relutrigine EMERALD readouts. Freenome's first tests reach the market.
• Q4 2026 / early 2027 — Tempus closes Personalis. Guardant's Shield cost per test drops ~15% on the new workflow.
• January 29, 2027 — FDA decision on Praxis's ulixacaltamide for essential tremor.
• H1 2027 — Intellia launches lonvo-z if approved. Guardant expects ADLT pricing for Guardant360 Liquid CDx. Natera expects the next leg of Signatera price increases as MolDX decisions land.
• 2027 — Tempus's $200/test price bump kicks in. Roche pushes Axelios toward clinical use.

The direction of travel is obvious. Blood tests replace scopes. One-time edits replace lifelong prescriptions. The only real questions are who gets paid and how fast. This list is the eleven answers we're tracking.